Xenon Pharmaceuticals Inc. (XENE) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$56.00
Price Target
$80.20
Target Range
$44.00 — $100.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-12.8x
Forward PEG—
Implied Growth-9.7%
Median Target$89.50
Analyst Spread69.8%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$44
-21.4%
Consensus
$80
+43.2%
Bull Case
$100
+78.6%
XENE Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Xenon Pharmaceuticals Inc. (XENE) has a Wall Street consensus price target of $80.20, based on estimates from 22 covering analysts. With the stock currently trading at $56.00, this represents a potential upside of +43.2%. The company has a market capitalization of $4.42B.
Analyst price targets range from a low of $44.00 to a high of $100.00, representing a 70% spread in expectations. The median target of $89.50 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 22 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, XENE trades at a trailing P/E of -12.8x. Analysts expect EPS to grow -9.7% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+33.5%
Avg Forward P/E24.9x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 PRAXPraxis Precision Medicines, Inc. | $9.6B | $333.28 | $544.40 | +63.3% | Buy | — | 16 |
 ACADACADIA Pharmaceuticals Inc. | $3.9B | $22.57 | $34.78 | +54.1% | Buy | 50.9x | 37 |
 PTCTPTC Therapeutics, Inc. | $5.3B | $64.49 | $89.67 | +39.0% | Buy | — | 26 |
 ARVNArvinas, Inc. | $652M | $10.19 | $13.00 | +27.6% | Buy | — | 26 |
 OVIDOvid Therapeutics Inc. | $355M | $2.73 | $3.50 | +28.2% | Buy | — | 14 |
 LGNDLigand Pharmaceuticals Incorporated | $4.1B | $210.33 | $267.75 | +27.3% | Buy | 23.6x | 17 |
 NKTRNektar Therapeutics | $1.7B | $83.37 | $132.83 | +59.3% | Buy | — | 33 |
 ABBVAbbVie Inc. | $358.4B | $202.64 | $256.64 | +26.6% | Buy | 14.3x | 41 |
 NVSNovartis AG | $277.4B | $145.39 | $141.00 | -3.0% | Hold | 16.6x | 25 |
 JNJJohnson & Johnson | $536.2B | $222.51 | $249.27 | +12.0% | Buy | 19.2x | 40 |
Upside Potential Comparison
PRAXNKTRACADPTCTOVIDARVNLGNDABBVSee XENE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XENE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare XENE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonXENE — Frequently Asked Questions
Quick answers to the most common questions about buying XENE stock.
What is the XENE stock price target for 2026?
The consensus Wall Street price target for XENE is $80.2, representing 43.2% upside from the current price of $56. With 22 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is XENE a buy, sell, or hold?
XENE has a consensus rating of "Buy" based on 22 Wall Street analysts. The rating breakdown is predominantly bullish, with 22 Buy/Strong Buy ratings. The consensus 12-month price target of $80.2 implies 43.2% upside from current levels.
Is XENE stock overvalued or undervalued?
XENE's current price is $56 with a consensus target of $80.2 (43.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can XENE stock go?
The most bullish Wall Street analyst has a price target of $100 for XENE, while the most conservative target is $44. The consensus of $80.2 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover XENE stock?
XENE is well covered by analysts, with 22 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 22 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the XENE stock forecast?
The 12-month XENE stock forecast based on 22 Wall Street analysts shows a consensus price target of $80.2, with estimates ranging from $44 (bear case) to $100 (bull case). The median consensus rating is "Buy".
Should I buy XENE stock?
Wall Street analysts are very optimistic on XENE, with a "Buy" consensus rating and $80.2 price target (43.2% upside). 22 of 22 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do XENE price targets vary so much?
XENE analyst price targets range from $44 to $100, a 70% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $80.2 consensus represents the middle ground.